BCR-ABL1gene fusion is seen in all of the following except
**Core Concept**
The BCR-ABL1 gene fusion is a result of a chromosomal abnormality involving the juxtaposition of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9, leading to the production of a constitutively active tyrosine kinase. This genetic abnormality is a hallmark of certain types of leukemia, including chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL).
**Why the Correct Answer is Right**
The BCR-ABL1 fusion is a result of a reciprocal translocation between chromosomes 9 and 22, specifically t(9;22)(q34;q11). This leads to the creation of a chimeric gene that encodes a protein with constitutive tyrosine kinase activity, driving the proliferation of leukemic cells. The BCR-ABL1 fusion is a critical diagnostic marker for CML and some cases of ALL.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because BCR-ABL1 is not typically associated with acute promyelocytic leukemia (APL), which is characterized by a different genetic abnormality, the PML-RARA fusion.
**Option B:** This option is incorrect because BCR-ABL1 is not typically associated with acute myeloid leukemia (AML) with a normal karyotype, which can have a variety of underlying genetic abnormalities.
**Option C:** This option is incorrect because BCR-ABL1 is not typically associated with Burkitt lymphoma, which is characterized by a different genetic abnormality, the c-MYC translocation.
**Clinical Pearl / High-Yield Fact**
The BCR-ABL1 fusion is a critical diagnostic marker for CML and some cases of ALL, and its presence has significant implications for treatment and prognosis.
**Correct Answer:** A